PT713495E - Metodos de aumento da bioactividade de quimocinas - Google Patents

Metodos de aumento da bioactividade de quimocinas

Info

Publication number
PT713495E
PT713495E PT94920701T PT94920701T PT713495E PT 713495 E PT713495 E PT 713495E PT 94920701 T PT94920701 T PT 94920701T PT 94920701 T PT94920701 T PT 94920701T PT 713495 E PT713495 E PT 713495E
Authority
PT
Portugal
Prior art keywords
methods
bioactivity
increased chemical
truncated
binding
Prior art date
Application number
PT94920701T
Other languages
English (en)
Inventor
Pradip Kumar Bhatnagar
Louis M Pelus
Andrew Garrison King
Joanna Maria Balcarek
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PT713495E publication Critical patent/PT713495E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT94920701T 1993-06-08 1994-06-03 Metodos de aumento da bioactividade de quimocinas PT713495E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7380093A 1993-06-08 1993-06-08

Publications (1)

Publication Number Publication Date
PT713495E true PT713495E (pt) 2004-03-31

Family

ID=22115875

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94920701T PT713495E (pt) 1993-06-08 1994-06-03 Metodos de aumento da bioactividade de quimocinas

Country Status (9)

Country Link
US (3) US6080398A (pt)
EP (2) EP0713495B1 (pt)
JP (1) JP4006021B2 (pt)
AT (1) ATE253637T1 (pt)
DE (1) DE69433301T2 (pt)
DK (1) DK0713495T3 (pt)
ES (1) ES2210255T3 (pt)
PT (1) PT713495E (pt)
WO (1) WO1994029341A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080398A (en) * 1993-06-08 2000-06-27 Smithkline Beecham Corporation Truncated gro and KC chemokines having enhanced bioactivity
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
AT403098B (de) * 1995-05-29 1997-11-25 Nycomed Austria Gmbh Antikörper zum nachweis und zur unterscheidung von verkürzten und nicht verkürzten formen von chemokinen
ZA968896B (en) * 1995-10-24 1997-04-24 Smithkline Beecham Corp Method of mobilizing hematopoietic stem cells
ZA969721B (en) * 1995-11-21 1997-11-28 Smithkline Beecham Corp Method of treating sepsis.
US6042821A (en) * 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US6852508B1 (en) * 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
WO1999028474A2 (en) * 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services Chemokine variants and methods of use
EP1303292A4 (en) * 2000-06-30 2007-08-22 Smithkline Beecham Corp CHEMOKINKONJUGATE
CA2561171A1 (en) * 2004-03-30 2005-10-20 Amylin Pharmaceuticals, Inc. Synthetic chemokines, methods of manufacture, and uses
BRPI0514343A (pt) * 2004-08-13 2008-06-10 Anormed Inc combinações de quimiocinas para mobilizar células progenitoras/tronco
US20100144641A1 (en) 2005-09-12 2010-06-10 Popel Aleksander S Compositions Having Antiangiogenic Activity and Uses Thereof
RU2009107030A (ru) * 2006-08-02 2010-09-10 Джензим Корпорейшн (Us) Комбинированная терапия
AR062271A1 (es) * 2006-08-07 2008-10-29 Genzyme Corp Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre
JP6037836B2 (ja) 2009-11-15 2016-12-07 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 特異的プロスタグランジンｅ２受容体の特定を含む幹細胞の送達及び生着を高めるための方法
EP2961828A4 (en) 2013-02-28 2016-08-03 Harvard College COMPOSITIONS AND METHOD FOR MOBILIZING STEM CELLS
BR112019021282A2 (pt) 2017-04-12 2020-05-19 Magenta Therapeutics Inc antagonistas de receptor aril hidrocarboneto e usos dos mesmos
US11267881B2 (en) * 2017-09-14 2022-03-08 Charles ROSSER Compositions and methods for treatment of diseases involving CXCL1 function
WO2019089833A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
AU2018358241A1 (en) 2017-10-31 2020-05-07 Edigene Biotechnology, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
JP2021505172A (ja) 2017-12-06 2021-02-18 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 造血幹細胞及び前駆細胞を動員させるための投薬レジメン
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
CN111902411A (zh) 2018-01-03 2020-11-06 美真达治疗公司 用于扩增造血干细胞和祖细胞以及治疗遗传性代谢紊乱的组合物和方法
EP4051298A1 (en) 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
CA3176979A1 (en) 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703206A (en) * 1981-09-08 1997-12-30 Univ Rockefeller Macrophage inflammatory protein 2 (MIP-2)
GB8626539D0 (en) * 1986-11-06 1986-12-10 Nycomed As Peptide compounds
ZW11290A1 (en) * 1989-07-14 1990-10-31 Smithkline Beecham Corp Hemoregulatory peptides
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
PT98072B (pt) * 1990-06-22 1998-11-30 Chiron Corp Processo para a preparacao de polipeptidos contendo proteina macrofagica inflamatoria humana mip-2 alfa por metodos recombinantes e de composicoes farmaceuticas que os contem
US5154921A (en) * 1990-07-13 1992-10-13 Dana-Farber Cancer Institute, Inc. Promotion of maturation of hematopoietic progenitor cells
JPH06503952A (ja) * 1990-09-28 1994-05-12 カイロン　コーポレイション Ｇｒｏ遺伝子、蛋白質、及びその使用
US6080398A (en) * 1993-06-08 2000-06-27 Smithkline Beecham Corporation Truncated gro and KC chemokines having enhanced bioactivity
ES2172536T3 (es) * 1993-06-15 2002-10-01 British Biotech Pharm Liberacion y movilizacion de celulas hematopoyeticas.
US5459128A (en) * 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
GB9426012D0 (en) * 1994-12-22 1995-02-22 British Biotech Pharm Mobilisation of haematopoietic cells

Also Published As

Publication number Publication date
JP4006021B2 (ja) 2007-11-14
US20040057925A1 (en) 2004-03-25
DE69433301T2 (de) 2004-09-09
US6399053B1 (en) 2002-06-04
ATE253637T1 (de) 2003-11-15
US6080398A (en) 2000-06-27
EP0713495A1 (en) 1996-05-29
WO1994029341A1 (en) 1994-12-22
DE69433301D1 (de) 2003-12-11
DK0713495T3 (da) 2004-03-08
ES2210255T3 (es) 2004-07-01
JPH08511167A (ja) 1996-11-26
EP0713495B1 (en) 2003-11-05
EP1378522A2 (en) 2004-01-07
EP0713495A4 (en) 1998-06-03
EP1378522A3 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
PT713495E (pt) Metodos de aumento da bioactividade de quimocinas
DE69008423D1 (de) Dynamische Fixierung von Schweinsaortaklappen.
MX9201212A (es) Agentes de control biologico.
FR2715847B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
NO885275L (no) Vaskulaere antikoagulantproteiner, dna'er som koder for dem, fremstilling og anvendelse derav.
NO880909D0 (no) Hydrofobisk modifiserte ikke-ioniske polygalactomannanethere.
NO910796L (no) Forbedrede biologiske insektkontrollmidler og fremgangsmaater ved bruk derav.
DE69736840D1 (de) Synthese von nukleosiden und polynukleotiden
ES2055234T3 (es) Agente con contenido de anticoagulante.
DE3870959D1 (de) 2-difluormethoxy-1,1,1,2-tetrafluoraethan als anaesthetikum.
DE69000828D1 (de) Sauerstoffsorbentmittel.
CA2008817A1 (en) M-csf monoclonal antibodies that recognize a neutralizing conformational epitope
FR2659658B1 (fr) Silice traitee par un organosilicone et composition la contenant.
NO167376C (no) Flertrinns biologisk renseanlegg.
CA2066263A1 (en) Tsh receptor
DE3778248D1 (de) 1,3-diarylcyclopentane und deren abkoemmlinge als paf-antagonisten.
FR2714062B1 (fr) Promoteur modifié pour ARN polymérase, sa préparation et ses applications.
DE69231940D1 (de) Rekombinant DNS kodierend für eine Endochitinase
ATE271125T1 (de) Neuartige tyrosinkinase
DE69116803D1 (de) Peroxidase-Gen von mikrobischem Ursprung
NO880517D0 (no) Biologisk respons-modifiseringsmiddel.
ES2073495T3 (es) Benzotiazepinas.
DE69421665D1 (de) Anomere Fluorribosylamine
EP0364587A4 (en) HEXAFLUORONEOPENTYL ALCOHOL, ITS DERIVATIVES, FLUORINATED POLYMERS AND THEIR USE.
ITBZ930026A0 (it) Procedimento per la movimentazione traslatoria di componenti ed azio- natore di movimento per l'attuazione del procedimento.